Savara (SVRA) – Analysts’ Weekly Ratings Updates

by · The Markets Daily

Several analysts have recently updated their ratings and price targets for Savara (NASDAQ: SVRA):

  • 10/15/2026 – Savara had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 10/7/2026 – Savara was given a new $10.00 price target by Royal Bank Of Canada.
  • 10/7/2026 – Savara had its “market outperform” rating reaffirmed by Citigroup.
  • 10/7/2026 – Savara is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $12.00 price target on the stock.
  • 10/4/2026 – Savara was downgraded by Wall Street Zen from “hold” to “sell”.
  • 9/26/2026 – Savara was upgraded by Wall Street Zen from “sell” to “hold”.

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s work is centered on conditions with significant unmet medical needs, particularly diseases involving impaired lung function and abnormal accumulation of material in the lungs.

Savara’s lead product candidate is molgramostim, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is being developed for autoimmune pulmonary alveolar proteinosis, a rare lung disorder in which surfactant accumulates in the airspaces and interferes with breathing.

Read More